Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
September 1, 2025: FDA Approves Wegovy for Fatty Liver Disease The FDA has granted a new indication for Wegovy (semaglutide) to treat metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease in adults with moderate to advanced fibrosis
However, side effectsparticularly nauseamay feel more intense if you eat immediately after injecting, because your stomach is already working to digest food while semaglutide simultaneously suppresses appetite and slows digestion
These drugs are metabolized primarily through proteolytic degradation by peptidases throughout the body, not through hepatic cytochrome P450 enzymes or biliary excretion pathways
Contact our office today to start the process of determining eligibility and filing a lawsuit against the makers of Mounjaro
